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Abstract
Primaquine (PQ) is a key drug in the malaria pre-elimination stage. However, PQ can trigger acute 
hemolysis for people with G6PD deficiency (G6PDd). In 2013, 15–25 million Indonesian people were infected 
with malaria, with 30,000–38,000 deaths each year mostly in eastern Indonesia with API= 15.6 %. Recently, the 
Ministry of Health of the Republic of Indonesia announced a plan to reach the pre-elimination stage based on 
WHO guidelines. This study assesses whether eastern Indonesia should proceed with the activities of malaria 
pre-elimination. A total 555 healthy people in five subdistricts in eastern Indonesia were selected by systematic 
random samping. All data were collected using a standard questionnaire, physical examination, and laboratory 
tests. PCR and DNA sequencing protocols followed respective manufacture’s instructions. Statistical analysis 
by bivariate with α= 0.05 and 95% CI were performed using the SPSS software package. Based on the nested 
PCR, the result showed a malaria prevalence of 32.6% with  being the dominant species (52.5%). Malaria 
cases were found in all study sites and not using a bed net was the moost significant risk factors with Exp B= 
1.54 with 95% CI= 0.99–2.38. G6PDd prevalence was 16.6%, the highest G6PDd ever found in Indonesia with 
variant molecular dominant  10.883 T>C and one sample with a heterozygous female. Malaria pre-elimination 
in eastern Indonesia should be delayed. High risk patients should be tested for enzyme G6PD activities before 
antimalarial administration.
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Introduction
Glucose-6-phosphate dehydrogenase 
(G6PD) is an X-linked essential enzyme 
that protects cells from oxidative stress, 
particularly in red blood cells (RBC). G6PD 
deficiency (G6PDd), the most common 
known enzymopathy, is a hereditary genetic 
defect and it is one of the most prevalent 
polymorphisms in humans, especially in 
males (Kyoung et al., 2014). G6PD is an enzyme 
that plays an important role in protecting 
cells from oxidative damage by producing 
nicotinamide adenine dinucleotide phosphate 
(NADPH) and reducing glutathione (GSH) 
in the erythrocyte. The G6PD gene is highly 
polymorphic with almost 400 reported 
variants, and is more commonly found 
in males than in females. This has led to 
the speculation that malaria has been the 
selection pressure that has favored the 
maintenance of this potentially deleterious 
trait. There is some evidence that hemizygous 
and heterozygous G6PDd may be protected 
against severe malaria. Most of individuals 
with G6PDd are normally asymptomatic, 
however, erythrocyte exposure to oxidative 
stress causes haemoglobin (Hb) denaturation, 
and ultimately results in haemolysis. 
Haemolytic anemia in G6PDd can be 
triggered by a range of oxidative agents, such 
as infections and certain foods and drugs, 
including antimalarial 8-aminoquinolines 
like primaquine (Luzattoet al., 2001; Beutler 
and Vullamy, 2002; Clark et al., 2009).
Primaquine is the 8-aminoquinolines, 
a class of drugs discovered almost 80 years 
ago. Primaquine is administered to patients 
infected with (hypnozoites)to prevent relapse 
as wll as with to reduce gametocyte carriage 
to block transmission (Beutler et al., 1995). 
People with G6PD deficiency more susceptible 
to hemolysis when taking primaquine. 
Recently, the Ministry of Health (MoH) of the 
Republic of Indonesia announced a plan to 
reach the pre-elimination stage by 2015–2020 
and to be free of malaria transmission by 
2030, and that it will use the World Health 
Organization (WHO) guidelines for pre-
elimination activities. WHO criteria for pre-
elimination are a reduction to zero incidence 
where the annual parasite incidence (API)= 
<1/1,000 population, no local transmission, 
and with no risk factors for three consecutive 
years (Elyazar et al., 2011; Kemenkes RI, 2013; 
WHO, 2014).
In 2011–2014, there were 4.8 million 
cases of malaria reported in eastern Indonesia 
with (62%) and (33%)being the most common 
species (Elyazar et al., 2011; WHO, 2014). In 
this region, malaria is the primary cause of 
mortality with 23,483 deaths.  South Central 
Timor (SCT)  District, one of the highest 
malaria prevalence rates in eastern Indonesia 
with API= 15.6% for more than 10 years 
following mother mortality rate (MMR) and 
infant mortality rate (IMR), twice higher than 
the national average (Kemenkes RI, 2013; 
Dinkes Prov. NTT, 2013; Dinkes TTS, 2014).
About 49 of 61 countries had failed 
to achieve malaria elimination in 2010. A 
review of resurgence in the Philippines and 
Thailand and two provinces in Indonesia, 
(Central Java and Kepulauan Seribu Island) 
that successfully pre-eliminated because 
of continued active control programs and 
passive case finding, and strong initiatives 
with neighboring countries, such as vector 
control, available operational drugs, and 
good surveillance systems (WHO, 2007; 
Feachem et al., 2010; Maharaj et al., 2012).
Malaria pre-elimination will be possible 
only with serious attempts to address 
asymptomatic and chronic infections by both 
and Currently in Indonesia, the available 
drugs that can completely clear a human 
of  for radical cure and that can reduce the 
transmission of malaria parasites are those in 
primaquine, however, people with G6PDd 
risk having severe adverse reactions such 
as hemolysis if exposed to these drugs at 
certain doses (Syafrudin et al., 2009; Kathy et 
al., 2010). Since 1989, primaquine has been 
administered in the Indonesian regions without 
any G6PDd testing, and to date, no study has 
been undertaken to ascertain the prevalence of 
G6PDd in SCT District. This study reports on 
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G6PDd prevalence and the variant molecular 
in a malaria endemic region regarding whether 
eastern Indonesia should proceed malaria pre-
elimination activities. 
Materials and methods 
Ethics statements
This study was approved by the ethics 
committee of the Faculty of Medicine, 
Universitas Gadjah Mada, Yogyakarta 
( reference  No:  KE/FK/85/EC).  Al l 
participants signed a written consent form 
and gave their permission for the collection 
of blood samples. 
Samples 
A survey was conducted from August 
2013 to September 2014. Sample size was 
calculated using a malaria prevalence 
of 15.6% in 2013 in South Central Timor 
District, eastern Indonesia (Lemenshow et 
al., 1997). Criteria for inclusion were  ≥14 
years of age and hemoglobin (Hb) level= ≥ 
11 gr/dL by using HemoCue (HemoCue, 
2013). Participants were interviewed face to 
face with a standard questionnaire, while 
household locations were obtained using the 
Garmin GPS 76, USA (Garmin International 
Inc., 2006). All participants underwent 
a physical examination by local health 
practitioners. During the interview, thick and 
thin blood smears (Giemsa 5%) were made 
for malaria identification (Eijkman Institute 
for Molecular and Kemenkes RI, 2010). 
Determination of G6PD activity
Commercial  quanti tat ive G6PD 
enzyme test kits was used to screen 
for G6PDd population. G6PD enzyme 
activities were calculated at 340 nm/min 
with a spectrophotometer at Biochemistry 
Laboratories, Faculty of Medicine, Universitas 
Gadjah Mada, Yogyakarta. All protocols to 
determine G6PD activities were according 
to manufacturer’s instructions from the 
Randox G6PD test. The reliability of test 
results was monitored by calibration and 
including controls provided by the Randox 
G6PD test. Activity G6PD mU/gHb = mU 
eritrosit per mL x 100/Hb g/dL. The normal 
G6PD activities enzymes = ≥ 6.97-20.5 U/gHb 
(Randox Laboratories Limited, 2013).
DNA extraction
Whole blood samples were collected 
in an EDTA anticoagulant tube, specifically 
a 5 mL BD Vacutainer 5 mL (BD life science, 
2014) and stored at -20°C for molecular 
assessment. DNA was extracted from 200 µL 
of whole blood using nucleon genomic DNA 
extraction kit (Promega Co., 2014).
G6PDd genotype variant detection
G6PD variants were detected using 
five sets of specific primers (20-25 ng/µL) 
from exon 5, 6, 9, 11, and 12 (Table 1). PCR 
amplification of G6PD gene was performed 
in 30 µL total reaction, which consisted of 
1 µL each primer (20 µM), 2 µL of DNA 
Table 1. G6PD primers sequence and annealing temperature (0C) for G6PD gene amplification. 
Exon PCR product size (bp)
Annealing 
temp (0C) Primers sequence
5 343 64,5 5-ACA-CAC-GGA-CTC-AAA-GAG-AG-3
5-TGG-TGG-GAG-CAC-TGC-CTG-3
6 320 65 5-TGG-GAG-GGC-GTC-TGA-ATG-AT-3
5-TGG-TCC-TCA-CGG-AAC-AGG-GAA-G-3
9 333 59 5-TCC-CTG-CAC-CCC-AAC-TCA-AC-3
5-AGT-GCG-TGA-GTG-TCT-CAG-T-3
11 157 65 5-TGG-CAT-CAG-CAA-GAC-ACT-CTC-TC-3
5-CCC-CAT-AGC-CCA-CAG-GTA-TGC-AGG-3
12 205 64 5-TGT-GTG-CCA-CCG-GCC-TCC-CA-3
5-ATG-AGG-TAG-CTC-CAC-CCT-CA-3
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template (20-25 ng/µL), green master mix 
PCR 15 µL and 11 µL distilled water. The 
PCR temperatures condition used were 30 
cycles of initial denaturation at 950C for 5 
min, annealing for 30 sec (table 1) and a 
final extension at 720C for 5 min for 30 cycles 
(Nguyen et al., 2008). Positive and negative 
controls were used. The PCR products were 
resolved by electrophoresis on 1.5% agarose 
gel, containing 5 µL ethidium bromide (EtBr) 
(Promega, USA). DNA ladder was used 
(Vivantis Tech, Malaysia). G6PD variants 
were detected by sequencing (ABI Prism 310 
genetic sequencer, Macrogen 2014). G6PDd 
were classified according to WHO G6PDd 
with five level criteria (Marina et al., 1998). 
We also re-confirmed the G6PD 
mutations that were found by PCR-RFLP 
using three variants most common in Asia 
(Nguyen et al., 2008) (Table 2). PCR-RFLP 
amplification was performed in 25 µL total 
reaction, with all protocols PCR-RFLP 
following the guidelines of KAPA HiFi, 
Boston, USA, cat. No. KK-2101 (Kappa 
Biosystems, 2013; Nicole 2014). The G6PD 
variants were Vanua Lava 10.884 T>C with 
enzyme restriction , Viangchan Jammu 
13.031 G>A with enzyme restriction Xba-
1, and Chatham 13.163 G>A with enzyme 
restriction BstX-1 (New England BioLabs, 
2013).
Plasmodium identification
Identification of species used double 
assignment, microscopic by Giemsa 5% and 
nested PCR with ten sets of primers. Nested-1 
Table 2. List of the primers sequences and annealing temperature (0C) for PCR-RFLP amplification.
Variant G6PD
Annealing 
temp (0C) Enzyme Primers sequence
PCR Product 
size
Viangchan /VC 56 Xba-1 5-TGG-CTT-TCT-CTC-AGG-TCT-AG-3
5-GTC-GTC-CAG-GTA-CCC-TTT-GGG-G-3
126 bp
Chatham /CT 61 Bst-X-1 5-CAA-GGA-GCC-CAT-TCT-CTC-CCT-T-3
5-TTC-TCC-ACA-TAG-AGG-AGG-ACG-    
GCT-GCC-AAA-GT-3
208 bp
Vanua Lava /
VL
65 Eco-N-1 5-CAG-CCT-GGG-GCA-GTG-TCT-GTG-
CT-3
5-GCG-GTT-GGC-CTG-TGA-CCC-CTG-
GTG-3
366 bp
The enzyme from NEB = 
Table 3. The primer sequence used for nested PCR and amplification of the species malariaidentification 
(Snounow  1993)
Primers Primers sequence Product size (bp)& annealing (0C)
Ist round PCR
r-PLU-5
r-PLU-6
Plasmodium genus detection
5-CTT –GTT-GTT-GCC-TTA-AAC-TTC
5-TTA-AAA-TTG-TTG-CAG-TTA-AAA-CG
1,2 kb/58o
2nd round PCR Species identification
r-FAL-1
r-FAL-2
5-TTA-AAC-TGG-TTT-GGG-AAA-ACC-AAA-TAT-ATT
5-ACA-CAA-TGA-ACT-CAA-TCA-TGA-CTA-CCC-GTC
205 bp/58,5o
r-VIV-1
r-VIV-2
5-CGC-TTC-TAG-CTT-AAT-CCA-CAT-AAC-TGA-TAC
5-ACT-TCC-AAG-CCG-AAG-CAA-AGA-AAG-TCC-TTA 
120 bp/55o
r-OVA-1
r-OVA-2
5-ATC-TCT-TTT-GCT-ATT-TTT-TAG-TAT-TGG-AGA
5-GGA-AAA-GGA-CAC-ATT-AAT-TGT-ATC-CTA-GTG 
800 bp/54o
r-MAL-1
r-MAL-2
5-ATA-ACA-TAG-TTG-TAC-GTT-AAG-AAT-AAC-CGC
5-AAA-ATT-CCC-ATG-CAT-AAA-AAA-TTA-TAC-AAA
144 bp/55o
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using primers r-PLU-5 and r-PLU-6 and 
nested-2 using primers are shown in Table 3.
Total nested PCR reaction 25 µL, PCR 
using protocols in accordance with Promega, 
Madison, USA (Cat. No. M-7122) with PCR 
condition followed from Snounow (1993). 
A positive control using known samples of 
and nuclease-free water is used as a negative 
control. 1.5% agarose gel from Bioron, 
Germany (Cat. No. 604001), containing 
5µl/mL ethidium bromide from Promega, 
Madison, USA (Cat. No. H-5041) was used 
for electrophoresis. Bands were visualized 
by ultra violet illumination with DNA ladder 
from Vivantis, Selangor, Malaysia, Cat. No. 
NL-1407.
Statistical analysis
This study was evaluated by univariate, 
bivariate (chi-square), and multivariate 
statistical analysis test with α = 0.05 and 
95% confident interval (CI) using the SPSS 
16.0 software package. G6PDd subjects 
were classified as normal and deficient of 
G6PD enzymatic activities on the basis of 
the Randox G6PD test (Ranjit, 1999; Martin, 
2000). 
Results and Discussion
Demography malaria and G6PD prevalence
A total 555 of 558 individuals who 
were screened in five subdistricts (Oinlasi, 
Oe’ekam, Panite, Batu Putih, and Oenino), 
systematically selected, and completed the 
questionnaire also provided blood samples 
for analyses of G6PD status and malaria 
(Figure 1).
The primary objective of this study 
was to describe the prevalence of G6PDd in 
eastern Indonesia. G6PDd prevalence was 
16.4% (91/555) and predominately female at 
56.5% (52/92). Amongst age groups, 41–51 
years old had the highest prevalence with 
30.4% (28/92). The current study was higher 
compared with previous reports from other 
parts of Indonesia, such as Sumba District 
(5.1%) and Flores District (7.5%), and Malaysia 
(3.4%), Vanuatu (6.9%), Korea (0.5%), and 
Vietnam (8.7%). Samples were selected from 
healthy individuals in the general population 
from particular malaria endemic areas, so 
it is surprising that G6PDd frequencies are 
divergent from previous reports. However, 
there are probably very few regions studied 
with regards to G6PD testing specifically in 
Indonesia (Ganczakowski et al., 1995; Ainoon 
2002; Nguyen et al., 2009; Matsuoka et al., 
2013; Satyagraha et al., 2015).
G6PDd prevalence was higher in three 
malaria endemic regions, Oinlasi Subdistrict 
(42.8%), Panite Subdistrict (20.8%) and 
Oe’ekam subistrict 16.5% where malaria 
status level high cases incidence and middle 
cases incidence. A high G6PDd was found in 
South Central Timor District, justified malaria 
transmission were unstable transmission area 
and high potential occurs malaria outbreak. 
G6PDd testing needs to be undertaken, because 
currently only primaquinine remains as the 
drug of choice for radical cure for hypnozoites 
and controlling malaria transmission, and the 
risk associated with its use must be minimized 
during pre-elimination (Nick et al., 2011; Goo 
et al., 2014). All patients with positive malaria 
should be tested for G6PD enzyme activities 
and adequately informed before primaquine 
is administered. In an individual with G6PDd, 
primaquine should be prescribed in lower 
doses. WHO suggested using an intermittent 
primaquine regimen of 0.75 mg base/kg once 
a week for eight weeks to help the malaria 
pre-elimination program (Kemenkes RI, 2010; 
Gonzalo et al., 2013).
Because the majority of respondents 
in this study were Timorese, it was also the 
dominant ethnicity with G6PDd (95.6%). 
Based on the results of the nested PCR, 22 
of the 91 G6PDd cases (24%) were infected 
with malaria with  being the most dominant 
species. 
Another important finding in this study 
was the prevalence of anemia (Hb = ≤11 g/
dL) in people with G6PDd (83 cases or 91%) 
and most respondents with G6PDd (98%) 
had a history of malaria infection (Table 
5). Of the risk factors, five variables were 
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significant: decreased Hb level P = <0.05 and 
OR = 1.26, abortion history P = <0.05 and OR 
= 1.04, antimalarial primaquine consuming P 
= <0.05 and OR = 1.14, favism diet P = <0.05 
and OR = 1.95 and malaria infection history 
P = <0.05 and OR = 1.07. G6PDd correlated 
reasonably well with decreased hemoglobin 
levels, with average G6PDd respondents’ 
mean Hb (11.7 g/dL) lower than the normal 
group (13.3 g/dL). G6PD activity significant 
with decreasing hemoglobin levels, in other 
words, anemia appeared to directly impact 
G6PD activity. The explanations for anemia 
are reticulocytemia among the anemia 
and natural decay as red blood cells age. 
These results are consistent with a study in 
the National Medical Center and Howard 
University, Washington DC, USA by Smith 
et al. (2009), which showed that G6PDd had 
a significant effect on Hb concentration; 
however, the G6PD activities level was no 
different in G6PD normal subjects versus 
those who were G6PD deficient (Jansen et al., 
1985; Lorenz et al., 2013; Mehdi et al., 2010).
Figure 1. Schematic work flow of this study on malaria prevalence, enzyme activity, and G6PD 
variants in eastern Indonesia.
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The primary objective of this study was to describe the prevalence of G6PDd 
in eastern Indonesia. G6PD  prevalence was 16.4% (91/555) and pr dominately 
female at 56.5% (52/92). Amongst age groups, 41–51 years old had the highest 
prevalence with 30.4% (28/92). The current study was higher compared with previous 
r ports from other parts of Indonesia, such as Sumba District (5.1%) and Flores 
District (7.5%), and Malaysia (3.4%), Vanuatu (6.9%), Korea (0.5%), and Vietnam 
Subjects recruited (n= 555) from 5 district 
a. 100 (18 %) Oinlasi 
b. 100 (18 %) Oe’ekam 
c. 100 (18 %) Panite 
d. 120 (21.6 %) Batu Putih 
e. 138 (24.7 %) O’enino 
Male:  229 (41.3 %) and Female: 326 (58.7 
%) 
G6PD deficiency (G6PDd) Randox quantitative test 
UK  
Cat. No: PD-410= 16.6 % (91/555) 
a. 40 % (40/100) Oinlasi 
b. 15 %  (15/100) Oe’ekam 
c. 19 % (19/100) Panite 
d. 5,8 % (7/120) Batu Putih 
e. 8,1 % (11/135) O’enino 
Male:  6.8 % (38/229) and Female: 9.7 % (53/326) 
Result of genotyping G6PD variant (reference no. X-
554481) 
a. Exon-5:  6,5 % (6/92) 10.883 T>C variant vanua lava 
b. Exon-6:  no mutation 
c. Exon-9: no mutation 
d. Exon-11: no mutation 
e. Exon-12: no mutation 
Male:  83.3 % (5/6) and Female: 16.6 % (1/6) 
Positive Plasmodium malaria infection (nested 
PCR)= 181/555= 32.6 %: 
a. 25 % (25/100) Oinlasi 
b. 45 % (45/100) Oe’ekam 
c. 25 % (25/100) Panite 
d. 35,8 % (43/120) Batu Putih 
e. 46,7 % (63/135) O’enino 
Male:  14% (78/555) and Female:  18.6 (103/555) 555 Quantitative 
G6PD assay testing 
555 Nested PCR 
Plasmodium detection 
(Venous blood) 
Genotyping: 
1. G6PDd  (92) 
2. Borderline (10) 
3. Normal (10) 
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The prevalence of malaria by nested PCR 
was higher than that based on microscopic 
results; 32.6% (181/555) and 1.6% (9/555), 
respectively, with  as the most dominant. 
There were more females (57%) than males 
(43%) infected by malaria and the age group 
with highest malaria infection was ≥51 years 
(35.9%). Overall, malaria cases were found in 
all districts and even in districts with a low 
cases incidence (LCI).
Even the prevalence of malaria was high 
and no variables significant (p = >005) to the 
malaria risk factors, but the OR = >1, in this 
study most of eastern Indonesia is living with 
endemic However, blood surveys for this 
parasite are unlikely to detect the dormant 
liver stage of infection, so the prospects 
for pre-elimination would be improve by 
combining G6PDd distribution, antimalarial 
therapy practices, and manageability of 
malaria infection risk (Carlos et al., 2008; Hay 
et al., 2007; Howes et al., 2012; ). 
G6PD Gene Genotype 
We also screened the nucleotide 
substitution position which absent from 
data based on G6PDd variant (WHO and 
Minucci et al.,2012). Sequence analysis 
presents a summary of molecular across five 
exons of the G6PD gene (5, 6, 9, 11, and 12). 
Genotype was available for 60.9% (56/92). 
However, only 8.9% (6/56) identified with 
the  variant (10.884 T>C) with one sample 
being a heterozygous female (Table 8).
Figure 2. The distribution of the G6PDd and malaria cases in Timor Tengah Selatan district, Nusa Tenggara Timur 
Province, Indonesia 
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Figure 2. The distribution of the G6PDd and malaria cases in Timor 
                Tengah Selatan district, Nusa Tenggara Timur Province, Indonesia  
 
G6PDd prevalence was higher in three malaria endemic regions, Oinlasi 
Subdistrict (42.8%), Panite Subdistrict (20.8%) and Oe’ kam subistrict 16.5% where 
malaria status level high cases incidence and middle cases incidence. A high G6PDd 
Oenino Subdistrict 
P. vivax =  3.1 % 
P.falciparum = 3.6 % 
G6PDd = 2 % 
Oinlasi Subdistrict 
P. vivax = 3.6 % 
P.falciparum = 0.4 % 
G6PDd = 7 %  
Panite  Subdistrict 
P. vivax = 1.8 % 
P.falciparum = 2 % 
G6PDd = 3.4 
Oe`ekam Subdistrict 
P. vivax = 3.2 % 
P.falciparum = 3.1 % 
G6PDd = 2.7 % 
Batu Putih Subdistrict 
P. vivax =  5.2 % 
P.falciparum = 1.3 % 
G6PDd = 1.3 % 
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An expected result we found was 
female heterozygous, 48 years old with 
lower range of enzymes G6PD activity <3.9 
U/grHb, and negative result malaria. This 
displayed a wide range of G6PD variant in 
eastern Indonesia. Heterozygosity imposes 
greater complexity to the consideration of 
primaquinine therapy. From the postulated 
evolution of G6PDd, it is possible that the 
frequency of malaria is lower in patients 
with G6PDd (White et al., 2012). We would 
conclude that heterozygous G6PDd females 
could perhaps prove vulnerable and very 
sensitive to antimalarial primaquine therapy 
in terms of risk of hemolytic anemia. Indeed 
screening for G6PDd prior to primaquinine 
therapy would likely be required to protect 
patients diagnosed with a infection (Marla 
et al., 2009).  
Malaria pre-elimination program in eastern 
Indonesia 
The malaria pre-elimination activities in 
eastern Indonesia should be delayed because 
Table 4. Distribution of G6PDd (quantitative test), South Central  Timor  District, Eastern 
Indonesia.
Variables G6PD-d result (quantitative) Total (%)
Deficiency (%) Non deficiency (%)
Sex:
Male 
Female 
40 (7.2)
52 (9.2)
189 (34.1)
275 (49.5)
229 (41.3)
326 (58.7)
Age groups (years):
< 15 
16-20
21-30
31-40
41-50
> 51
0 (0)
2 (0.4)
18 (3.2)
17 (3.1)
28 (5.0)
26 (4.7)
11 (2.0)
12 (2.2)
63 (11.4)
136 (24.5)
105 (18.9)
137 (24.7)
11 (2.0)
14 (2.5)
81 (14.6)
153 (27.6)
133 (24.0)
163 (29.4)
Subdistrict:
Oinlasi
Oe’ekam
Panite
Batu Putih
Oenino
39 (7.0)
15 (2.7)
19 (3.4)
7 (1.3)
11 (2.0)
61 (11.0)
85 (15.3)
81 (14.6)
113 (20.4)
124 (22.3)
100 (18.0)
100 (18.0)
100 (18.0)
120 (21.6)
135 (24.3)
Ethnicity:
Belunese
Sumbanese
Rotenese
Sabunese
Timorese
Others* 
1 (0.2)
1 (0.2)
1 (0.2)
1 (0.2)
87 (15.7)
0 (0)*
0 (0)
2 (0.4)
25 (4.5)
6 (1.1)
425 (76.6)
6 (1.0)*
1 (0.2)
3 (0.5)
26 (4.7)
7 (1.3)
512 (92.3)
6 (1.0)*
Nested PCR result:
. 
. 
 and 
Negative 
5 (0.9)
11 (2.0)
6 (1.1)
0 (0)
69 (12.4)
52 (9.4)
84 (15.1)
23 (4.1)
0 (0)
305 (55.0)
57 (10.3)
95 (17.1)
29 (5.2)
0 (0)
374 (67.4)
Haemoglobin level:
Normal (11 gr/dl)
Anaemia (<11 gr/dl)
8 (1.4)
83 (15.0)
197 (35.5)
267 (48.1)
205 (36.9)
350 (63.1)
Historyof infected malaria:
Yes
No
2 (0.4)
89 (16.0)
37 (6.7)
427 (76.9)
39 (7.0)
516 (93.0)
Total 91 (16.4) 464 (83.6) 555 (100)
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they do not meet the WHO guidelines of an 
API of <1/1,000 population (Rajendra et al., 
2012). The prevalence of malaria based on 
this study by nested PCR (32.6%) was still 
high compared with the microscopic test 
result (1.6%), with dominating. In order to 
achieve pre-elimination according to WHO, 
API must reach <1 case per 1000 people, 
unfortunately this assessment’s results were 
not consistent with the national plans for 
pre-elimination by 2015−2020 (Kemenkes RI, 
2010). Malaria is a major public health burden 
in eastern Indonesia affecting vast regions. 
Based on a health office report from 2005 to 
2010, there were outbreaks in 19 provinces, 
covering 65 districts with 58,152 cases and 
536 reported deaths CFR = >0.9% (Elyazar 
et al., 2011).
Table 5. Bivariate analysis on G6PDd risk factors (α= 0.05 with 95% CI).
Variables G6PDd result OR/P-value
95% CI
(+) deficiency (%) Normal (%) Lower-Upper
Malaria endemic 
malaria:
 ≤ 5 years
 ≥6 years
12 (2.2)
79 (14.2)
60 (10.8)
404 (72.8)
1.04 (0.53) 0.89-1.12
Haemoglobin (Hb) level:
Anaemia (<11 gr/dl)
Normal (±11 gr/dl)
83 (15)
8 (1.4)
267 (48.1)
197 (35.5)
1.26 (0.00)* 1.18-1.34*
Abortion history:
Yes (+)
No (-)
4 (0.7)
87 (15.7)
54 (9.7)
410 (73.9)
1.04 (0.02)* 1.04-1.22*
History antimalarial:
Yes (+)
No (-)
2 (0.4)
89 (16)
37 (6.7)
427 (76.9)
1.14 (0.03)* 1.05-1.24*
Favism diet:
Yes (+)
No (-)
19 (3.4)
72 (13.0)
47 (8.5)
417 (75.1)
1.95 (0.05)* 1.26-3.02*
Others Infection history:
Yes (+)
No (-)
39 (7.0)
52 (9.4)
183 (33)
280 (50.5)
0.97 (0.31) 0.90-1.05
Malaria infected:
Positive (+)
Negative (-)
22 (4.0)
69 (12.4)
159 (28.6)
305 (55)
1.07 (0.03)* 1.00-1.15*
*p=<0.05 (significant)/other infections=Thyfoid, dengue and chikungunya/
OR=odds ratios/CI 95%=confident interval.
a b
Figure 3. DNA sequencing result of heterozygous female G6PDd, female (SCT-233), 48 years old, negative 
malaria, (a) forward primer, and (b) reverse primer. Nucleotide subtitution 10.884 C>T at codon 128 exon-5. 
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To address malaria pre-elimination 
many interventions have been carried out. 
Residual spraying with insecticides (initially 
DDT), rapid diagnostic tests, artemisinin-
based combination therapy (ACT), and 
surveillance have been introduced since 
2005 (Noor et al., 2010). In successful cases 
in Central Java Province, Jembrana (Bali 
Island), and Sabang District (Aceh Province) 
intervention focused solely on malaria pre-
elimination with seven recommended steps: 
(1) producing a map of endemicity and foci 
of malaria, (2) assessing the feasibility of 
collaboration between communities and 
government, (3) developing a strategic plan 
for malaria control, (4) support from the 
district health office and legislative council, 
(5) developing an integrated working plan, 
(6) implementing the working plan, and (7) 
monitoring and evaluating the strategy and 
the progress made (Omumbo et al., 2005; 
Herdiana et al., 2013).
Table 6. The distribution of malaria cases by nested PCR result. 
Variables
Malaria infections based on by nested PCR 
Total (%)P. falciparum (%) P. vivax (%) P. falciparumand  P.vivax (%)
Total infected 
(%)
Sex:
Male
Female
23 (29.5)
34 (33)
43 (55.1)
51 (49.5)
12 (15.4)
18 (17.5)`
78 (34.1)
103 (31.6)
229 (41.3)
326 (58.7)
Age groups  (years):
≤ 15 
16-20
21-30
31-40
41-50
≥ 51
1 (33)
3 (75)
6 (33.3)
15 (31.9)
8 (18.2)
24 (36.9)
2 (67)
0 (0.0)
7 (33.9)
25 (53.2)
30 (68.2)
30 (46.1)
0 (0.0)
1 (25)
5 (27.8)
7 (14.9)
6 (13.6)
11 (16.9)
3 (27.3)
4 (28.6)
18 (22.2)
47 (30.7)
44 (33.1)
65 (39.9)
11 (2.0)
14 (2.5)
81 (14.6)
153 (27.6)
133 (24.0)
163 (29.4)
Subdistrict:
Oinlasi (HCI)
Oe’ekam (HCI)
Panite (MCI)
Batu Putih (LCI)
Oenino (LCI)
2 (8)
17 (37.8)
11 (44)
7 (16.3)
20 (31.7)
20 (80)
18 (40)
10 (40)
29 (67.4)
17 (26.9)
3 (12)
10 (22.2)
4 (16)
7 (16.3)
6 (9.5)
25 (25)
45 (45)
25 (25)
43(35.8)
63 (46.7)
100 (18.0)
100 (18.0)
100 (18.0)
120 (21.6)
135 (24.3)
Ethnic:
Timorese 
Sabunese
Rote
Bugis
Sumbanese
Others*
54 (32.5)
1 (33.3)
2 (18.2)
0 (0.0)
0 (0.0)
0 (0.0)*
84 (50.6)
2 (66.7)
8 (72.7)
0 (0.0)
0 (0.0)
0 (0.0)*
28 (16.8)
0 (0.0)
1 (9.1)
0 (0.0)
0 (0.0)
1 (100)*
166 (32.4)
3 (42.8)
11 (42.3)
0 (0)
0 (0)
1 (16.7)
512 (92.3)
7 (1.3)
26 (4.7)
1 (0.2)
3 (0.5)
6 (1.0)*
Length of stay (years):
 ≤ 5 
 ≥ 6 
50 (31.4)
7 (31.8)
82 (51.6)
12 (54.5)
27 (16.9)
3 (13.6)
159 (32.9)
22 (30.5)
483 (87.0)
72 (13.0)
Haemoglobin (Hb):
1. Anemia (≤10 g/dl)
2. No anemia (>10 g/
dl)
34 (30.4)
23 (33.3)
58 (51.8)
36 (52.2)
20 (8.4)
10 (14.5)
112 (32)
69 (33.6)
350 (36.9)
205 (36.9)
Antimalarial drug 
history:
1. Yes
2. No
5 (38.5)
52 (30.9)
6 (46.2)
88 (52.4)
2 (15.4)
28 (16.7)
13 (33.3)
168 (32.6)
39 (7.0)
516 (93.0)
 * Others=Sundanese, Sundanese, Batak and Chinese/* Malariae and ovale negative for all survey participant/HCI= 
high cases incidence API>5‰/MCI= middle cases incidence= API 2-4‰/LCI= low cases incidence= API <1‰.
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This study suggests that more active 
and passive case finding coupled with 
periodic Mass Blood Surveys (MBS), case 
management with effective drugs, vector 
control, and good surveillance is needed. The 
conception is very different and rather more 
complex in the remaining eastern Indonesia 
and the absolute feasibility of this goal would 
need to be further assessed with additional 
work. The situation is entirely different in 
other province in Indonesia. Reducing high 
risk because a lot of remote areas, limited 
development of healthcare facilities, systems 
delivering prompt diagnosis, effective 
treatment including services are the challenge 
we should manage to achieve malaria pre-
elimination in eastern Indonesia (David et 
al., 2013).
For the population at risk estimates 
will allow malaria control managers for 
vector control interventions, help forecast the 
number of Long-Lasting Insecticide Treated 
Nets (LLINs) that need to be procured and 
distributed. The cost estimates of scaling 
Table 7. Bivariate analysis on malaria risk factors in eastern Indonesia.
Variables
Nested PCR result
 (Plasmodium identification) Odds Ratios (OR)
95% CI
Positive (%) Negative (-) Lower-Upper
Sex:
Male
Female
78 (14.1)
103 (18.6)
151 (27.2)
223 (40.2)
1.07 0.84-1.37
Visited others district:
Yes
No
76 (13.7)
105 (18.9)
154 (27.7)
220 (39.6)
1.02 0.80-1.30
Using bed nets:
Yes 
No
146 (26.3)
35 (6.3)
274 (49.4)
100 (18)
1,52 0.98-2.35
Sleeping out of the house at night (field):
Yes 
No
46 (8.3)
134 (24.2)
94 (17)
280 (50.5)
1.01 0.77-1.33
Screen ventilation used:
 Yes
 No
3 (0.5)
177 (32.0)
2 (0.4)
371 (67.1)
1.85 0.89-3.83
Living near cattle shed:
Yes
No
124 (22.3)
57(10.3)
251 (45.2)
123 (22.2)
1.04 0.80-1.35
Mosquitos breeding places near home:
Yes
No
144 (25.9)
37 (6.7)
306 (55.1)
68 (12.3)
1.05 0.90-1.22
* Significant variable (p=<0.05)
Table 8. The sequencing alignment result on G6PD gene mutation (accession reference no. X-554481).
Exon No. sample mutation (%)
Nucleotide (nt) position 
substitution
Codon/
Amino acid 
substitution
Class 
G6PDd 
WHO
Variant 
G6PDd
5 6 (6.4) 10.884 T>C 128 Leu>Pro II
6 0 (0) - - - No mutation
9 0 (0) - - - No mutation
11 0 (0) - - - No mutation
12 0 (0) - - - No mutation
*C=Cytosin/T=Timin/Leu=Leusina/Pro=Prolina
I.J. Biotech, Vol. 20, No. 2
128
Hutagalung et al.
up LLIN coverage can also be calculated; 
however, the distribution of the malaria 
transmitted and the distribution G6PDd 
need evaluation before any intervention is 
scaled up (Carlos et al., 2008). The mapping 
analysis showed that transmission is not 
homogeneous. Malaria risk is displayed in a 
whole area of study site. This map provide 
the base for designing a surveillance strategy 
and will be fully implemented by targeted 
inland hotspot for prevent an outbreak. 
The endemicity maps were used to estimate 
real incidence malaria and G6PD in areas 
for pre-elimination. The new methods with 
serologic assignment is needed to support 
the pre-elimination program (Howes et al., 
2012; Supargiyono et al., 2013). 
There are limitations in this study. 
When selected participants are from a 
healthy population we cannot describe the 
real signs and symptoms due to the effect of 
G6PDd and malaria. Therefore, this study 
requires further exploration in prospective 
studies.   
Conclusion and recommendation
In summary, our survey of G6PD in 
eastern Indonesia variant  (10.884 T>C) was 
relatively common within Asia and eastern 
Indonesia. Primaquine treatment has the 
potential to induce oxidative stress, and has 
a significant risk of causing decreased Hb 
or adverse hemolysis. Therefore, a G6PD 
assessment should be conducted before 
antimalarial drug administration. The 
malaria pre-elimination program in eastern 
Indonesia should be delayed. Instead, 
routine treatment to stop silent transmission, 
outbreak control, and further tests on G6PDd 
is required before the administration of 
primaquinine, and more sensitive laboratory 
support is needed before the pre-elimination 
program is carried out. 
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